Related Experiment Video
Updated: Aug 3, 2026
19:57
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods
1ARUP Institute for Clinical and Experimental Pathology, University of Utah Health Sciences Center, 500 Chipeta Way, Salt Lake City, UT 84108, USA. eralimc@arup-lab.com
Journal of Clinical Microbiology
|May 29, 2001
Summary
Two HIV drug resistance genotyping assays showed high concordance, but interpretation and reporting varied. Further standardization is needed for reliable HIV-1 drug resistance testing.
Area of Science:
- Virology
- Molecular Biology
- Clinical Diagnostics
Background:
- Genotypic assays are increasingly used to determine drug resistance in human immunodeficiency virus (HIV) type 1.
- Current genotypic tests for HIV-1 drug resistance lack standardization and validation.
- Accurate drug resistance profiling is crucial for effective HIV treatment regimens.
Purpose of the Study:
- To evaluate and compare the performance of two commercially available genotypic assays for HIV-1 drug resistance.
- To assess the concordance between two specific genotypic assays and an independent reference laboratory.
- To identify challenges in the analysis, interpretation, and reporting of HIV-1 drug resistance genotyping data.
Main Methods:
- Comparison of Visible Genetics TruGene HIV-1 Genotyping Kit and Applied Biosystems HIV Genotyping System using 22 clinical samples.
- Validation of results against an independent reference laboratory.
- Assessment of mutation identification, concordance rates, and sequencing capabilities at varying viral loads.
Main Results:
- Both Visible Genetics and Applied Biosystems assays demonstrated high concordance (99%) in identifying HIV-1 drug resistance mutations.
- The reference laboratory showed greater variability in mutation identification compared to the two commercial assays.
- Both assays could sequence samples with 500-750 HIV RNA copies/ml, generating accurate sequences.
- Only Visible Genetics reports provided direct links between mutations and drug resistance.
Conclusions:
- The Visible Genetics and Applied Biosystems genotypic assays are technically similar and generate accurate HIV-1 drug resistance sequence data.
- Differences in databases and reference strains can influence mutation identification.
- Standardization of data analysis, interpretation, and reporting, particularly linking mutations to drug resistance, is essential for clinical application.
